Your browser is no longer supported. Please, upgrade your browser.
RCKT Rocket Pharmaceuticals, Inc. daily Stock Chart
RCKT [NASD]
Rocket Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own2.10% Shs Outstand56.67M Perf Week-1.78%
Market Cap780.91M Forward P/E- EPS next Y-1.94 Insider Trans23.44% Shs Float50.05M Perf Month-27.85%
Income-77.30M PEG- EPS next Q-0.49 Inst Own95.00% Short Float15.11% Perf Quarter-38.01%
Sales- P/S- EPS this Y16.70% Inst Trans0.11% Short Ratio17.99 Perf Half Y14.45%
Book/sh6.00 P/B2.30 EPS next Y6.30% ROA-25.30% Target Price36.29 Perf Year-28.49%
Cash/sh5.37 P/C2.57 EPS next 5Y10.80% ROE-32.00% 52W Range9.01 - 27.59 Perf YTD-39.46%
Dividend- P/FCF- EPS past 5Y14.60% ROI- 52W High-50.05% Beta2.60
Dividend %- Quick Ratio16.80 Sales past 5Y- Gross Margin- 52W Low52.94% ATR1.74
Employees57 Current Ratio16.80 Sales Q/Q- Oper. Margin- RSI (14)42.50 Volatility8.87% 15.07%
OptionableYes Debt/Eq0.15 EPS Q/Q40.80% Profit Margin- Rel Volume1.22 Prev Close14.18
ShortableYes LT Debt/Eq0.15 EarningsMar 05 Payout- Avg Volume420.36K Price13.78
Recom1.60 SMA20-2.37% SMA50-26.71% SMA200-15.09% Volume514,868 Change-2.82%
Nov-06-19Initiated Chardan Capital Markets Buy $30
Sep-26-19Initiated Piper Jaffray Overweight
Apr-23-19Initiated Robert W. Baird Outperform
Mar-15-19Initiated BofA/Merrill Buy $27
Feb-05-19Initiated Oppenheimer Outperform $39
Sep-13-18Initiated Ladenburg Thalmann Buy $30
Jul-10-18Initiated William Blair Outperform
Apr-02-20 09:00AM  Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic Business Wire +6.46%
Mar-27-20 10:04AM  Why Rocket (RCKT) Stock Might be a Great Pick Zacks -9.48%
Mar-19-20 07:00AM  Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease Business Wire +32.85%
Mar-05-20 07:00AM  Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights Business Wire
Feb-24-20 07:00AM  Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia Business Wire
Feb-18-20 07:00AM  Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Feb-11-20 09:15AM  Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021 Business Wire
Feb-06-20 07:00AM  Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness Business Wire
Jan-09-20 09:44AM  What You Must Know About Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Beta Value Simply Wall St.
Jan-06-20 12:00PM  Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy Zacks
07:00AM  Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-29-19 03:24AM  Corporate Insiders Pull the Trigger on 3 Buy-Rated Stocks TipRanks
Dec-16-19 07:00AM  Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia Business Wire +7.26%
Dec-13-19 04:01PM  Rocket Pharmaceuticals Announces Closing of Public Offering Business Wire
12:37PM  Did Hedge Funds Drop The Ball On Rocket Pharmaceuticals, Inc. (RCKT) ? Insider Monkey
Dec-11-19 07:21AM  The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga -13.99%
Dec-10-19 10:45PM  Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire +5.44%
04:01PM  Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
12:00PM  Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy Zacks
07:56AM  The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-09-19 07:00AM  Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I Business Wire
Dec-08-19 06:00PM  Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 "Process B" for Fanconi Anemia at 61st American Society of Hematology Annual Meeting Business Wire
Dec-06-19 07:00AM  Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 "Process B" for Fanconi Anemia Business Wire +13.47%
Dec-05-19 07:00AM  Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting Business Wire
Dec-04-19 09:27AM  Rocket Pharmaceuticals, Inc. (RCKT) Shares March Higher, Can It Continue? Zacks
Nov-27-19 07:00AM  Rocket Pharmaceuticals Announces Participation at Upcoming Conferences TEST Business Wire Releases
Nov-07-19 07:00AM  Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights Business Wire
Nov-06-19 09:00AM  Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 Process B for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting Business Wire
Nov-05-19 07:00AM  Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit Business Wire
Nov-01-19 11:16AM  Should You Buy Rocket Pharmaceuticals, Inc. (RCKT)? Insider Monkey
Oct-24-19 07:00AM  Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 Process A for Fanconi Anemia Business Wire
Oct-22-19 07:00AM  Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency Business Wire
Oct-15-19 07:00AM  Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress Business Wire +8.24%
Oct-01-19 07:00AM  Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference Business Wire
Sep-23-19 07:00AM  Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency Business Wire
Sep-10-19 07:00AM  Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine Business Wire +5.96%
Sep-04-19 07:00AM  Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting Business Wire
Aug-28-19 07:00AM  Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Aug-22-19 07:00AM  Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia Business Wire
Aug-07-19 07:00AM  Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights Business Wire
Jul-31-19 07:00AM  Rocket Pharmaceuticals Announces Participation at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference Business Wire
Jun-25-19 09:24PM  Heres What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT) Insider Monkey
11:30AM  A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Simply Wall St.
Jun-18-19 07:00AM  Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome Business Wire
May-29-19 10:00AM  Rocket Pharmaceuticals Sponsors 3rd Annual PKD Patients Forum Business Wire
May-23-19 03:00PM  Did You Manage To Avoid Rocket Pharmaceuticals's (NASDAQ:RCKT) 19% Share Price Drop? Simply Wall St.
May-09-19 01:54PM  Heres What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT) Insider Monkey
May-08-19 07:13AM  Rocket Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights Business Wire
May-07-19 07:00AM  Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference Business Wire
May-02-19 07:00AM  Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting Business Wire
Apr-30-19 07:00AM  Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM) Business Wire -6.31%
Apr-18-19 11:20AM  Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Apr-16-19 08:10AM  The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
Apr-15-19 10:36PM  Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire
04:01PM  Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
12:49PM  Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting Business Wire
Mar-15-19 08:00AM  Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting Business Wire +5.43%
Mar-12-19 07:22AM  Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock? Simply Wall St.
07:00AM  Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S. Business Wire
Mar-11-19 07:00AM  Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA) Business Wire +5.52%
Mar-07-19 07:00AM  Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights Business Wire -5.58%
Mar-05-19 07:00AM  Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire -6.42%
Feb-28-19 08:00AM  Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019 Business Wire
Feb-26-19 07:00AM  Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology Business Wire
Feb-20-19 07:00AM  Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire
Jan-22-19 07:00AM  Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease Business Wire -5.71%
Dec-21-18 07:00AM  Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index Business Wire -7.66%
Nov-30-18 12:00PM  Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-27-18 08:02PM  Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire
08:37AM  Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher Zacks
07:00AM  Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia Business Wire
Nov-26-18 04:15PM  Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire +7.16%
08:36AM  Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome Business Wire
08:36AM  Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector Business Wire
08:36AM  REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector PR Newswire
Nov-25-18 04:00PM  Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program Business Wire
Nov-19-18 07:00AM  Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I) Business Wire
Nov-07-18 07:01AM  Rocket Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights Business Wire
07:00AM  Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia Business Wire
Nov-01-18 09:08AM  Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire +6.69%
Oct-19-18 07:00AM  Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) Business Wire
Oct-18-18 07:00AM  Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) Business Wire -9.84%
Sep-25-18 07:00AM  Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Aug-30-18 07:00AM  Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences Business Wire
Aug-08-18 07:32AM  Rocket Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM  Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights Business Wire
Jun-22-18 07:00AM  Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes Business Wire
May-30-18 07:00AM  Rocket Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference Business Wire
May-18-18 04:00PM  Rocket Pharmaceuticals Presents Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in Patients with Fanconi Anemia at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Business Wire
May-17-18 07:00AM  Rocket Pharmaceuticals Announces Strategic Research Collaboration Business Wire -6.56%
May-15-18 07:00AM  Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. Food and Drug Administration Director of the Office of Orphan Products Development, as Vice President, Regulatory Policy and Patient Advocacy Business Wire +5.54%
May-11-18 07:00AM  Rocket Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights Business Wire
May-08-18 07:00AM  Rocket Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Apr-30-18 02:30PM  Rocket Pharmaceuticals Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Business Wire
Apr-02-18 10:45AM  We Are Seeing a Dreary Liquidation in the Stock Market TheStreet.com -8.48%
10:29AM  Looking for Market Leadership TheStreet.com
Mar-06-18 07:00AM  Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights Business Wire
Mar-05-18 07:00AM  Rocket Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference Business Wire
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction. The company also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, it has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The company has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. It also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. The company is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah GauravPresident & CEOMar 24Option Exercise0.4390,92539,0981,061,642Mar 26 07:48 PM
Patel KinnariChief Operating OfficerMar 18Buy9.501,0009,5006,675Mar 19 07:56 PM
Shah GauravPresident & CEOFeb 25Option Exercise0.43290,000125,628976,950Feb 27 05:36 PM
RTW INVESTMENTS, LPDirectorDec 10Buy22.25225,0005,006,25017,282,324Dec 12 03:43 PM